Skip to content

Exercise Training to Improve PTSD Symptoms and Health in Older Veterans

Exploring the Effects of Exercise Training on PTSD Symptoms and Physical Health in Older Veterans With PTSD

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04199182
Enrollment
80
Registered
2019-12-13
Start date
2021-06-07
Completion date
2025-02-28
Last updated
2026-03-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Post-traumatic Stress Disorder

Keywords

Physical performance, Veterans, Aged, Exercise, HRQOL

Brief summary

Posttraumatic stress disorder (PTSD) is prevalent among military Veterans and is more than just a psychological condition; PTSD has profound negative impacts on health, function, and quality of life. Older Veterans are the largest patient population served by the Veterans Health Administration (VHA), and many have lived with PTSD for 40+ years. Veterans with PTSD engage in low levels of physical activity and spend much of their time in sedentary activities, adding to their risk of physical disability. The benefits of exercise on mental health and physical well-being in older adults are well-substantiated, but the effects of exercise training on late-life PTSD symptoms is a new area of study. This study is designed to examine the effects of 6 months of supervised exercise training on PTSD symptoms and PTSD-related conditions (e.g., functional impairment, sleep) in 188 older Veterans with PTSD.

Interventions

BEHAVIORALExercise Training

A multi-component group exercise intervention that emphasizes functional training. Duration is 6 months, and frequency is 3x per week.

OTHERHealthy Aging Attention Control (HA-ATC)

Participants in the HA-ATC group will receive a health education program modeled on the "10 Keys to Healthy Aging" curriculum and the National Council on Aging's "Aging Mastery Program." HA-ATC will include an 8-week face-to-face group program followed by bi-weekly sessions for the remaining 4 months.

Sponsors

VA Office of Research and Development
Lead SponsorFED

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Investigator, Outcomes Assessor)

Intervention model description

Behavioral intervention testing the effects of supervised exercise versus attention-control on PTSD symptoms and function.

Eligibility

Sex/Gender
ALL
Age
65 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Veteran status * registered for care at Durham VA Health Care System (VAHCS) * live within 50 miles of fitness facility * meet diagnostic criteria for PTSD as assessed by the CAPS-5

Exclusion criteria

* history of any psychiatric disorder with severe psychotic features in the past 5 years (e.g., bipolar disorder, mania), as indicated by ICD-10 codes F20-F29 (ICD-9 category 298.9) * prominent suicidal ideation or hospitalization for suicidality in the previous 6 months * clinically significant: neurological disorder, systemic illness affecting central nervous system (CNS) function, or history of seizure disorder in the past 5 years * uncontrolled diabetes defined as: * Abnormal fasting plasma glucose 126 mg/dL, random plasma glucose 200 mg/dL * no active medications for diabetes management (Metformin, insulin, etc.) * no clinical notes in the patient's electronic health record (EHR) indicating monitoring by primary care physician (PCP) or Endo for diabetes management) * end stage liver disease or currently receiving dialysis * physical disabilities precluding use of exercise equipment (assistive mobility devices acceptable) * significant cognitive impairment or diagnosis of Alzheimer's Disease or Dementia * hospitalization or ER visit in the past 6 months for conditions contraindicated for exercise (cardiac event; physical trauma)

Design outcomes

Primary

MeasureTime frameDescription
Clinician-Administered PTSD Scale for DSM-V (CAPS-5) Change Baseline to 6 Months6 monthsPTSD symptoms over the previous month will be assessed with the CAPS-5 clinical interview. Total symptom severity score and symptom cluster severity scores will be calculated. Scores range from 0 to 80, with higher scores reflecting more severe PTSD symptoms.
Six-minute Walk Test Change From Baseline to 6 Months6 monthsPerformance-based measure of aerobic endurance. Participants are instructed to walk along a measured course for 6 minutes. The distance walked in 6 minutes is the outcome of this assessment. There is no maximum value for this test, but the minimum value could be 0 (unable to walk any distance).

Secondary

MeasureTime frameDescription
Patient Health Questionnaire (PHQ-9) Change From Baseline to 6 Months6 monthsSelf-report tool for assessing the severity of depression. Scores range from 0 to 27, with higher scores indicating more severe depressive symptoms.
Pittsburgh Sleep Quality Index (PSQI) Change From Baseline to 6 Months6 monthsThe PSQI is a self-report tool for assessing sleep quality and disturbance. Scores on the PSQI range from 0 to 21, with higher scores indicating poorer sleep quality.

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORKatherine Shepherd Hall, PhD

Durham VA Medical Center, Durham, NC

Participant flow

Recruitment details

The participants are explained the nature, purpose, and procedure of the study and asked to sign an informed consent that will explain the potential risks and benefits of the study participation.

Baseline characteristics

Characteristic
Age, Continuous71.3 Years
STANDARD_DEVIATION 4.3
Clinician-Administered PTSD Scale for DSM-V (CAPS-5)27.4 units on a scale
STANDARD_DEVIATION 9.32
Ethnicity (NIH/OMB)
Hispanic or Latino
1 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
77 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
2 Participants
Patient Health Questionnaire (PHQ-9)11.5 units on a scale
STANDARD_DEVIATION 5.5
Pittsburgh Sleep Quality Index (PSQI)11.8 units on a scale
STANDARD_DEVIATION 4.3
Sex: Female, Male
Female
6 Participants
Sex: Female, Male
Male
67 Participants
Six-minute walk test452.9 Meters
STANDARD_DEVIATION 146.2

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 410 / 39
other
Total, other adverse events
14 / 416 / 39
serious
Total, serious adverse events
0 / 410 / 39

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 26, 2026